source
- EQT to acquire Qiagen in €10.8 billion dealEQT, a private‑equity firm, announced it will purchase Dutch molecular diagnostics company Qiagen in a transaction valued at €10.8 billion, including €1.1 billion of net debt. The deal follows a f…
- Roche's Genentech reports 43% reduction in kidney damage marker in phase 3 IgA nephropathy trialRoche Genentech disclosed detailed results from its phase 3 IMAgINATION trial of the antisense oligonucleotide sefaxersen in patients with IgA nephropathy. The trial showed a 43.1% greater reducti…